MedTrace Logo

Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma

NCT00817258 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2009-01-06

No results posted yet for this study

Summary

The primary objective of this study is to determine the overall survival in patients with stage II (T1-2N1M0) NPC treated with concurrent chemotherapy and radiotherapy.

Secondary objectives of the study are to evaluate the disease free survival, and distant metastases free survival of patients with stage II NPC treated with this regimen

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

cisplatin

Cisplatin 40mg/m2,weekly

RADIATION

3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)

3D-CRT or IMRT

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Lin Kong, MD · Department of Radiation Oncology, Cancer Hospital, Fudan University

  • Chaosu Hu, MD · Department of Radiation Oncology, Cancer Hospital, Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-06-30
Completion
2009-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817258 on ClinicalTrials.gov